Financial institutions, including UBS and Deutsche Bank, upgraded Elevance Health to Buy rating on May 28, 2026, while it operates as a health insurer in the United States.

1 report, 1 independent Updated May 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Elevance Health, Inc.UBS Deutsche Bank

Keep exploring

Part of

Multiple financial institutions, including Goldman Sachs, Morgan Stanley, Bank of America, UBS, and others, provided ratings and price targets for Marvell Technology on May 28, 2026. All 2 developments

The entities involved

Elevance Health, Inc.
American healthcare company
- Elevance Health offers services through Carelon brand.Thu 15:32
- Robeco Institutional Asset Management B.V. lifted its stake in Elevance Health shares and filed a 13F with the SEC.Thu 12:11
UBS
Swiss multinational investment bank and financial services company
- Multiple major banks, including Citigroup, UBS, Bank of America, and Barclays, have issued updated price targets and ratings.17:02
- Citigroup and UBS raised their price targets for Procter & Gamble.17:02
Deutsche Bank
German global banking and financial services company
- BOJ sets overnight call-rate guideline while Deutsche Bank comments on yen buying.01:36
- OPay, one of Nigeria's largest mobile-money platforms, is planning a listing in the United States, with Deutsche Bank hired to lead the process.Fri 23:43

Related events

Coverage

Newest first; wire copies grouped

May 28yahoo.com